Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.

Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, Li Y, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J; CISNET-BOLD Collaborative Group.

J Natl Cancer Inst. 2018 Sep 18. doi: 10.1093/jnci/djy128. [Epub ahead of print]

PMID:
30239794
2.

Investigation of phonatory characteristics using ex vivo rabbit larynges.

Döllinger M, Kniesburges S, Berry DA, Birk V, Wendler O, Dürr S, Alexiou C, Schützenberger A.

J Acoust Soc Am. 2018 Jul;144(1):142. doi: 10.1121/1.5043384.

PMID:
30075689
3.

Concern Regarding Age Distribution of Breast Cancer.

Cronin KA, Berry DA.

JAMA Surg. 2018 Jul 25. doi: 10.1001/jamasurg.2018.2087. [Epub ahead of print] No abstract available.

PMID:
30046830
4.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM.

Clin Cancer Res. 2018 Jul 23. doi: 10.1158/1078-0432.CCR-17-3431. [Epub ahead of print]

PMID:
30037817
5.

Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.

Plevritis SK, Berry DA, Mandelblatt JS.

JAMA. 2018 Jun 12;319(22):2336. doi: 10.1001/jama.2018.4261. No abstract available.

PMID:
29896623
6.

Signature program: a platform of basket trials.

Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A.

Oncotarget. 2018 Apr 20;9(30):21383-21395. doi: 10.18632/oncotarget.25109. eCollection 2018 Apr 20.

7.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.

Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA; CISNET-BOLD Collaborative Group .

J Natl Cancer Inst. 2018 Apr 28. doi: 10.1093/jnci/djy059. [Epub ahead of print]

PMID:
29718314
8.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.

Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.

9.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

PMID:
29554472
10.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

11.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

PMID:
29278430
12.

Influence of glottal closure on the phonatory process in ex vivo porcine larynges.

Birk V, Kniesburges S, Semmler M, Berry DA, Bohr C, Döllinger M, Schützenberger A.

J Acoust Soc Am. 2017 Oct;142(4):2197. doi: 10.1121/1.5007952.

PMID:
29092569
14.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

PMID:
28814435
15.

A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.

Huang X, Li Y, Song J, Berry DA.

Med Decis Making. 2018 Apr;38(1_suppl):78S-88S. doi: 10.1177/0272989X17714473. Epub 2017 Jun 19.

PMID:
28627297
16.

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP.

JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580. Epub 2017 Jul 13.

17.

Automated setup for ex vivo larynx experiments.

Birk V, Döllinger M, Sutor A, Berry DA, Gedeon D, Traxdorf M, Wendler O, Bohr C, Kniesburges S.

J Acoust Soc Am. 2017 Mar;141(3):1349. doi: 10.1121/1.4976085.

PMID:
28372097
18.

Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.

Domenyuk V, Zhong Z, Stark A, Xiao N, O'Neill HA, Wei X, Wang J, Tinder TT, Tonapi S, Duncan J, Hornung T, Hunter A, Miglarese MR, Schorr J, Halbert DD, Quackenbush J, Poste G, Berry DA, Mayer G, Famulok M, Spetzler D.

Sci Rep. 2017 Feb 20;7:42741. doi: 10.1038/srep42741.

19.

A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network.

Mawocha SC, Fetters MD, Legocki LJ, Guetterman TC, Frederiksen S, Barsan WG, Lewis RJ, Berry DA, Meurer WJ.

Clin Trials. 2017 Jun;14(3):246-254. doi: 10.1177/1740774516688900. Epub 2017 Jan 31.

20.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.

21.

PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology.

Blumenschein G Jr, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C.

J Thorac Oncol. 2016 Nov;11(11S):S307. doi: 10.1016/j.jtho.2016.09.094. Epub 2016 Oct 28. No abstract available.

22.

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply.

Berry DA.

JAMA Oncol. 2017 Mar 1;3(3):416-417. doi: 10.1001/jamaoncol.2016.3947. No abstract available.

PMID:
27892985
23.

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.

24.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.

25.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

26.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

27.

Dynamic vocal fold parameters with changing adduction in ex-vivo hemilarynx experiments.

Döllinger M, Berry DA, Kniesburges S.

J Acoust Soc Am. 2016 May;139(5):2372. doi: 10.1121/1.4947044.

28.

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA.

JAMA Oncol. 2016 Jun 1;2(6):751-60. doi: 10.1001/jamaoncol.2015.6113.

PMID:
26914222
29.

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, Berry DA.

Alzheimers Dement (N Y). 2016 Feb 4;2(1):1-12. doi: 10.1016/j.trci.2016.01.001. eCollection 2016 Jan.

30.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

31.

Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.

Guetterman TC, Fetters MD, Legocki LJ, Mawocha S, Barsan WG, Lewis RJ, Berry DA, Meurer WJ.

Clin Res Regul Aff. 2015 Oct 2;32(4):121-130. Epub 2015 Sep 18.

32.

Emerging innovations in clinical trial design.

Berry DA.

Clin Pharmacol Ther. 2016 Jan;99(1):82-91. doi: 10.1002/cpt.285. Epub 2015 Nov 19. Review.

PMID:
26561040
33.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

34.

Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer.

Berry DA.

Clin Cancer Res. 2016 Jan 1;22(1):3-5. doi: 10.1158/1078-0432.CCR-15-1903. Epub 2015 Oct 28.

35.

Advancing Clinical Trials to Streamline Drug Development.

Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH.

Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039.

36.

CNS Anticancer Drug Discovery and Development Conference White Paper.

Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC.

Neuro Oncol. 2015 Nov;17 Suppl 6:vi1-26. doi: 10.1093/neuonc/nov169.

37.

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ.

J Clin Oncol. 2015 Nov 1;33(31):3583-90. doi: 10.1200/JCO.2015.62.4148. Epub 2015 Aug 24. Review.

38.

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Sep;262(3):434-9; discussion 438-9. doi: 10.1097/SLA.0000000000001417.

39.

Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.

Berry DA, Hudis CA.

JAMA Oncol. 2015 Oct;1(7):875-6. doi: 10.1001/jamaoncol.2015.1293. No abstract available.

PMID:
26181139
40.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA.

Lancet Oncol. 2015 Jun;16(6):630-7. doi: 10.1016/S1470-2045(15)70168-3. Epub 2015 May 13. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

41.

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD.

Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):192-9. doi: 10.1097/WAD.0000000000000093.

PMID:
25973909
42.

Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis.

Legocki LJ, Meurer WJ, Frederiksen S, Lewis RJ, Durkalski VL, Berry DA, Barsan WG, Fetters MD.

BMC Med Ethics. 2015 May 3;16:27. doi: 10.1186/s12910-015-0022-z.

43.

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Berry DA.

Mol Oncol. 2015 May;9(5):951-9. doi: 10.1016/j.molonc.2015.02.011. Epub 2015 Mar 11. Review.

44.

The Signature Program: Bringing the Protocol to the Patient.

Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, Stein S, Salvado A.

Clin Pharmacol Ther. 2015 Aug;98(2):124-6. doi: 10.1002/cpt.126. Epub 2015 May 11.

45.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

46.

Commentary on Hey and Kimmelman.

Berry DA.

Clin Trials. 2015 Apr;12(2):107-9. doi: 10.1177/1740774515569011. Epub 2015 Feb 3. No abstract available.

PMID:
25649111
47.

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM.

Neuro Oncol. 2015 Aug;17(8):1106-13. doi: 10.1093/neuonc/nou345. Epub 2015 Jan 7.

48.

Reply to V. Amoroso et al.

Shulman LN, Berry DA, Cirrincione CT, Hudis CA, Winer EP.

J Clin Oncol. 2015 Jan 20;33(3):291. doi: 10.1200/JCO.2014.59.1875. Epub 2014 Dec 15. No abstract available.

PMID:
25512457
49.

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML.

J Natl Compr Canc Netw. 2014 Nov;12(11):1629-49.

50.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

Supplemental Content

Loading ...
Support Center